GLG News Analyses of the following article:
St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device with AF Suppression Technology
Published at: salesandmarketingnetwork.com
-
March 26, 2007
1. This technology has been in SJM pacemakers for long enough that we know AF is not eliminated - merely reduced in amount
2. Reduction in AF burden does not translate into reduced need for anticoagulation in this high risk population
3. Reduction in AF burden does not translate into reduction in clinical end-points such as stroke
4. The AF-suppression algorithm increases heart rate significantly and may (in theory) undermine the benefits of CRT
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.